Vinorelbine Tartrate

• CAT Number: A000151
• CAS Number: 125317-39-7
• Molecular Formula: C₄₅H₅₄N₄O₈.C₈H₁₂O₁₂
• Molecular Weight: 1079.11
• Purity: ≥95%
• Synonyms: Vinorelbine ditartrate; 125317-39-7; KW 2307; Nor-5/’-anhydrovinblastine ditartrate; C45H54N4O8.2C4H6O6
• Target: Others
• Solubility: >33.7mg/mL in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,2
• InChIKey: CILBMBUYJCWATM-NPJYPKOYSA-N
• SMILES: CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O

Vinorelbine Tartrate（Cat No.:A000151）is a semi-synthetic vinca alkaloid used as a chemotherapy agent, particularly effective in treating non-small cell lung cancer (NSCLC) and breast cancer. It works by disrupting microtubule formation, thereby inhibiting mitosis and inducing apoptosis in rapidly dividing cancer cells. Vinorelbine Tartrate is often administered intravenously or orally and can be used alone or in combination with other chemotherapeutic agents. Its targeted mechanism and relative tolerability make it a key option in oncology, providing significant benefits in managing various solid tumors.

Reference

1: Jimeno A, Hitt R, Quintela-Fandino M, Cortés-Funes H. Phase II trial of
vinorelbine tartrate in patients with treatment-naive metastatic melanoma.
Anticancer Drugs. 2005 Jan;16(1):53-7. PubMed PMID: 15613904.

2: Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT,
Tchekmedyian NS, Sondak VK; Southwest Oncology Group. A Phase II trial of
vinorelbine tartrate in patients with disseminated malignant melanoma and one
prior systemic therapy: a Southwest Oncology Group study. Cancer. 2004 Apr
15;100(8):1699-704. PubMed PMID: 15073859.

3: Uoshima N, Yoshioka K, Tegoshi H, Wada S, Fujiwara Y, Satake N, Kasamatsu Y,
Yokoho S. Acute respiratory failure caused by vinorelbine tartrate in a patient
with non-small cell lung cancer. Intern Med. 2001 Aug;40(8):779-82. PubMed PMID:
11518124.

4: Bosque E. Possible drug interaction between itraconazole and vinorelbine
tartrate leading to death after one dose of chemotherapy. Ann Intern Med. 2001
Mar 6;134(5):427. PubMed PMID: 11242511.

5: Kanazawa J, Morimoto M, Ohmori K. [Properties of antitumor activity of
vinorelbine tartrate, a new vinca alkaloid antitumor agent]. Nihon Yakurigaku
Zasshi. 2000 Oct;116(4):215-23. Review. Japanese. PubMed PMID: 11084918.

6: Giannios J, Ginopoulos P. Induction of PCD in tamoxifen-resistant oestrogen
receptor positive (ER+) advanced breast cancer after combined therapy with ER
antisense oligonucleotides and vinorelbine-tartrate encapsulated in DRV
liposomes. Eur J Cancer. 2000 Sep;36 Suppl 4:103. PubMed PMID: 11056347.

7: Feun LG, Savaraj N, Hurley J, Marini A, Lai S. A clinical trial of intravenous
vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced
malignant melanoma. Cancer. 2000 Feb 1;88(3):584-8. PubMed PMID: 10649251.

8: Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate
and heparin sodium. Am J Health Syst Pharm. 1999 Sep 15;56(18):1891. PubMed PMID:
10511236.

9: Cattan CE, Oberg KC. Vinorelbine tartrate-induced pulmonary edema confirmed on
rechallenge. Pharmacotherapy. 1999 Aug;19(8):992-4. PubMed PMID: 10453972.

10: Kouroukis C, Hings I. Respiratory failure following vinorelbine tartrate
infusion in a patient with non-small cell lung cancer. Chest. 1997
Sep;112(3):846-8. PubMed PMID: 9315826.